At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD, from National Cancer Center, Kashiwa, Japan, reviews promising approaches for the treatment of patients with gastrointestinal cancer, including molecular targeted therapies and clinical studies of anti-PD-1 antibodies, such as pembrolizumab, for advanced gastric or gastroesophageal junction adenocarcinoma.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement